Anixa biosciences stock.

When Anixa Biosciences last reported its balance sheet in January 2023, it had zero debt and cash worth US$28m. Importantly, its cash burn was US$7.3m over the trailing twelve months. So it had a ...Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA SecuritiesAnixa Biosciences, Inc. (ANIX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 2.9600 +0.1000 (+3.50%) At close: 12:59PM EST. 1d.Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Analyst Recommendations on Copytele Inc. HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating. Mar. 23. MT. Chardan Adjusts Price Target on Anixa Biosciences to $9 From $8, Keeps Buy Rating. Mar. 22. MT. Chardan Initiates Anixa Biosciences With Buy Rating, $8 Price Target. Dec. 23.About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a …

Mar 22, 2021 · Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock. News provided by. Anixa Biosciences, Inc. 22 Mar, 2021, 17:18 ET. SAN JOSE, Calif., March 22, 2021 /PRNewswire ... Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.

Get Anixa Biosciences Inc (ANIX.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsOct 3, 2023 · SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ... ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.In July 2023, Anixa Biosciences had US$26m in cash, and was debt-free. In the last year, its cash burn was US$5.8m. That means it had a cash runway of about 4.4 years as of July 2023.

Phone Number 6315495974. Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer ...

Anixa is focused on the treatment and prevention of cancer. Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology. Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.

SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and ...Anixa Biosciences, Inc. 3150 Almaden Expressway. Suite 250 San Jose, CA 95118 408-708-9808 [email protected] The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of …Brooklyn, NY 11219. Phone: 800-937-5449. Who are Anixa Biosciences' independent auditors? Haskell & White LLP. Who is Anixa Biosciences' outside legal counsel? Ellenoff Grossman & Schole LLP. 1345 Avenue of the Americas. New York, NY 10105-0302. Who can I contact for general information about Anixa Biosciences?Oct 31, 2023 · Anixa Biosciences plunges on upsizing stock offering to $22.5M SA News Tue, Mar. 23, 2021 2 Comments. Anixa Biosciences to raise $10M in bought deal offering SA News Mon, Mar. 22, 2021 1 Comment.

Anixa Biosciences' cash burn of US$5.8m is about 5.2% of its US$113m market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.Sep 21, 2023 · ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA SecuritiesSAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and ...

May 22, 2023 · SAN JOSE, Calif., May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in ... ANIX: Anixa Biosciences broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.

According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $10.83 with a high of $12.00 and a low of $9.00.SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused...SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused...Dec 1, 2023 · Anixa Biosciences Inc ANIX Morningstar Rating Unlock Stock XNAS Rating as of Dec 1, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... Jul 11, 2023 · Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual ... Sep 28, 2018 · SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (NASDAQ: ITUS ), a biotechnology company focused on using the body's immune system to fight cancer, today ... 18 Okt 2023 ... Anixa Biosciences; A Brief Investor Q&A With CEO and Chairman Amit Kumar, PhD. 3 views · 5 minutes ago ...more ...SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and ...

SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...

See Anixa Biosciences, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading ...

With a price/sales ratio of 433.5, ANIXA BIOSCIENCES INC has a higher such ratio than 99.07% of stocks in our set. Equity multiplier, or assets relative to ...Looking more specifically, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry, which includes 554 individual stocks and currently sits at #78 in the Zacks Industry Rank.Nov 21, 2023 · Get Anixa Biosciences Inc (ANIX.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Anixa Biosciences' cash burn of US$5.8m is about 5.2% of its US$113m market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.Stock Information. Quote; Charts; Historical Data; Analyst Coverage. ... Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr ...About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine …The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Anixa Biosciences, Inc. (ANIX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.2700 -0.0700 (-2.10%) At close: 04:00PM EST 3.2000 -0.07 ( …

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt ...Anixa Biosciences, Inc. Stock price Equities ANIX US03528H1095 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials …Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board October 23, 2023 Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial Instagram:https://instagram. how to buy roblox stockoption paper tradingmonster stocksbest fidelity bond index funds Anixa Biosciences, Inc. Common Stock (ANIX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. who buys broken iphones near mem.h.o SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 - 3, 2023. The presentation, entitled 'Infusion of Autologous T Cells …Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and ... trendspider review Chardan Capital analyst Matthew Barcus maintained a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $9.00.The company’s shares opened today at $4.12 ...In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences ( ANIX – Research Report ), with a price target of $12.00. The company’s shares closed ...